Skip to main content

Altered endotoxin responsiveness in healthy children with Down syndrome



Down syndrome (DS) is the most common syndromic immunodeficiency with an increased risk of infection, mortality from sepsis, and autoinflammation. Innate immune function is altered in DS and therefore we examined responses in CD11b and Toll like receptor 4 (TLR-4), which are important immune cell surface markers upregulated in response to Lipopolysaccharide (LPS) endotoxin, and the immunomodulator melatonin. Neutrophil and monocyte responses to LPS and melatonin in children with Down syndrome (DS) who were clinically stable were compared to age-matched controls. Whole blood was incubated with LPS and melatonin and the relative expression of CD11b and TLR-4 evaluated by flow cytometry.


Children with DS had an increased response to LPS in neutrophils and intermediate monocytes, while also having elevated TLR-4 expression on non-classical monocytes compared to controls at baseline. Melatonin reduced CD11b expression on neutrophils, total monocytes, both classical and intermediate sub-types, in children with DS and controls.


Melatonin could represent a useful clinical adjunct in the treatment of sepsis as an immunomodulator. Children with DS had increased LPS responses which may contribute to the more adverse outcomes seen in sepsis.


Down syndrome (DS) is caused by an extra copy of genetic material from chromosome 21, and is the most prevalent chromosomal abnormality, affecting approximately 1 in 550 births in Ireland [1], and 1 in 700 births in the USA [2]. Co-morbidities associated with DS include developmental disability, congenital heart disease (CHD), gastrointestinal tract anomalies, and an increased risk of haematological malignancy [3]. In addition, it is the most common genetic syndrome associated with abnormal immune function and immune defects [4]. There is significant evidence of immune dysregulation in Down syndrome including T-cell and B-cell lymphopenia due to impaired expansion of these cell lines in infancy [5], a smaller thymus gland with reduced naïve Tcell and regulatory T-cell numbers [6], suboptimal antibody responses to vaccination [7,8,9,10], and abnormal levels of serum cytokines [11,12,13].

Children with Down syndrome are, therefore, at increased risk of infection, especially in early childhood, particularly respiratory tract infections [14]. Hilton et al. [15] reported a higher risk of admission to hospital and intensive care with respiratory tract infections (RTIs) in children with DS. Mortality from sepsis is 30% greater in patients with DS in comparison to children without DS who also had sepsis [16].

It is challenging to attribute causation to a specific deficit of the immune system with the increased incidence of infections and sepsis seen in this cohort. A normal innate immune system is crucial in providing first line defence against infection. Neutrophils and monocytes are crucial cellular components of the innate immune system. Defective phagocytic activity and neutrophil chemotaxis have previously been reported in DS [17, 18]. Monocyte function in DS is poorly described. Increased numbers of the non-classical (CD14dim/CD16+) monocyte pro-inflammatory sub-type have been described in DS in comparison to controls [19]. This monocyte population has previously been implicated in sepsis and chronic disease [20].

CD11b is a cell surface marker involved in mediating neutrophil and monocyte adhesion and diapedesis [21] and is an indicator of activation. Dysfunction in neutrophil adherence and migration has been shown to increase the risk of infection in adults and neonates [22]. Toll-like receptor 4 (TLR-4) is the key receptor involved in lipopolysaccharide (LPS) endotoxin recognition and activation of the innate immune system [23], and has also been implicated in the pathogenesis of autoimmune conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis [24].

Immunomodulators can alter responses to infection, alleviate autoimmunity and ultimately improve patient care. Melatonin is an endogenous hormone which mediates its anti-inflammatory effects by modulating pro-inflammatory cytokines and inflammasome de-activation, thereby ameliorating results in endotoxaemia [25, 26]. Melatonin has a very good safety profile and is used in paediatrics in sleep management [27]. Clinical trials in adults and neonates with sepsis have demonstrated improved clinical outcomes [28, 29].

We hypothesized that children with DS have altered neutrophil and monocyte function which contributes to their increased susceptibility to infection and increased mortality from sepsis. We aimed to evaluate the in vitro effect of LPS endotoxin, and the anti-inflammatory melatonin on CD11b and TLR4 expression on neutrophils and monocytes in children with DS.


Study population

This study was approved by the ethics committees in the National Children’s Hospital, Tallaght and Our Lady’s Children’s Hospital, Crumlin (OLCHC), Dublin, Ireland. All parents and participants received verbal and written information on the study and written consent was obtained in advance of recruitment. There were two patient groups studied: a) Healthy children with Down syndrome < 16 years old attending the dedicated Down syndrome clinic. All children were clinically well with no recent fever or evidence infection and were undergoing annual routine health surveillance and b) Age-matched Controls: healthy controls attending phlebotomy or for day case procedures. Blood sampling occurred at induction of general anaesthetic and controls had no recent fever or evidence of infection.

Experimental design

All blood samples (1-3 mL) for in vitro experiments were collected in a sodium citrate anti-coagulated blood tube and analysed within 2 h of sample acquisition. Blood sampling coincided with routine phlebotomy or at induction of anaesthesia for day case procedures. Whole blood was incubated at 37 °C for 1 h with the pro-inflammatory stimulant Lipopolysaccharide (LPS; E.coli 0111:B4: SIGMA Life Science, Wicklow, Ireland) 10 ng/mL, the anti-inflammatory agent Melatonin (SIGMA Life Science, Wicklow, Ireland) at 42 μM and both combined.

Blood samples were incubated with a dead cell stain (100 μL; (Fixable Viability Dye eFlour 506, Invitrogen, California USA), diluted to working concentration in phosphate buffered saline (PBS). The following fluorochrome-labelled monoclonal antibodies (mAb) were added to each sample (2.5 μL per tube): CD14-PerCP, CD15-PECy7, CD16-FITC, CD66b-Pacific Blue and TLR4-APC (BioLegend®, California, USA) and PE labelled CD11b (BD Biosciences, Oxford, UK; 10 μL per tube. PBA buffer (PBS containing 1% bovine serum albumin and 0.02% sodium azide) was used to make up the antibody cocktail. Samples were incubated in the dark for 15 min. Next 1 mL of FACS lysing solution (BD Biosciences, Oxford, UK) was added to each tube, the samples were then incubated for 15 min in the dark. Cells were pelleted by centrifugation at 450 g for 7 min at room temperature, washed twice with PBA buffer and fixed in 300 μL of 1% paraformaldehyde. The final cell pellet was resuspended in 100 μL PBA buffer and analysed on a BD FACS Canto II flow cytometer.

Quantification of cell surface antigen expression

The expression of CD11b and TLR-4 antigens on the surface of neutrophils and monocytes was evaluated by flow cytometry on the BD FACS Canto II cytometer. Neutrophils were delineated based on SSC-A and CD66b + positivity as previously described [30], monocytes were defined based on SSC-A, CD66b- and subsets based on relative CD14+ CD16+ populations; classical (CD14+/CD16-), intermediate (CD14+/CD16+), non-classical (CD14dim/CD16+), Fig. 1. A minimum of 10,000 events were collated and relative expression of CD11b and TLR-4 was expressed as mean channel fluorescence (MFI), and analysed using FloJo software (Oregon, USA). Every sample was processed and analysed by the same researcher (DH) thereby reducing variability in results.

Fig. 1

Gating strategy for isolation of granulocytes and monocyte sub-populations. Neutrophils were delineated based on SSC-A and CD66b + positivity. Monocytes were defined based on SSC-A, CD66b- and subsets based on relative CD14+ CD16+ populations; classical (CD14+/CD16-), intermediate (CD14+/CD16+), non-classical (CD14dim/CD16+)


Statistical analysis was done using paired and un-paired t tests to compare mean results between two independent cohorts. Significance was defined as p < 0.05. Results shown are expressed as mean +/− standard error of the mean (SEM) unless otherwise stated. Data was analysed with FloJo software (Oregon, USA) and GraphPad Prism.


Patient characteristics

There were 23 healthy children with Down syndrome (DS) with a mean ±SD age of 8.67 ± 4 years(y) of which 13 were female (57%), and 21 healthy controls with a mean age of 7.4 ± 4.60 y, of which 10 were female (48%). In the DS cohort, children with a history of significant congenital heart disease requiring surgery in infancy (n = 7) were all clinically stable with no further cardiology intervention. All control participants had no significant medical history. Both groups were well at the time of blood sampling with no recent history of infection.

Effects of LPS endotoxin on CD11b expression

Neutrophil baseline CD11b expression in children with DS was significantly lower compared with controls (p = 0.045). Following incubation with LPS, CD11b significantly increased in both groups (Fig. 1a: DS p < 0.0001; Control p = 0.0001). When comparing the fold increase in CD11b expression from baseline, children with DS had a significantly higher rise after LPS stimulation (DS: Controls: 116% versus 62.4%; p = 0.03; Fig. 3a).

CD11b expression on total monocytes showed no difference at baseline or after LPS stimulation between both groups (Fig. 2b p = 0.48). The percentage rise of CD11b expression after LPS was similar in both groups also (DS versus Control: 53 v 55%; p = 0.92 Fig. 4b). Monocyte subset CD11b expression analysis revealed no significant differences at baseline or after LPS stimulation in classical (CD14+/CD16-) (p = 0.74), and non-classical (CD14dim/CD16+) (p = 0.21) sub-populations in children with DS versus controls (Figs. 2c, e and 4c (p = 0.55), e (p = 0.56)). Intermediate monocytes (CD14+/CD16+) demonstrated no difference in CD11b expression at baseline in children with DS and controls (p = 0.87). After LPS stimulation there was a significant increase in CD11b in children with DS (p = 0.004) but not in controls (p = 0.78; Fig. 2d). The mean percentage rise in CD11b expression in children with DS was not significantly increased compared to controls (DS vs controls: 31.8 v 5.8%; p = 0.088; Fig. 4d).

Fig. 2

Neutrophil and monocyte CD11b expression in response to lipopolysaccharide (LPS) in children with Down syndrome (DS) and controls. Values expressed as mean channel fluorescence (MFI). *p < 0.05. a Neutrophil CD11b (DS n = 23; Controls n = 16); b Total monocyte CD11b (DS n = 19; Controls n = 21); c Classical monocyte CD11b (DS n = 19; Controls n = 21; d Intermediate monocyte CD11b (DS n = 18; Controls n = 20); e Non-classical monocyte (DS n = 19; Controls n = 21)

Classical monocytes (CD14+/CD16-) exhibited the highest CD11b expression at baseline compared with the other sub-populations in both cohorts (DS vs Control -classical vs intermediate: p = 0.009 v 0.01). This sub-population also demonstrated the largest mean percentage rise in CD11b after LPS treatment in both children with DS and controls. (DS – classical % rise vs intermediate vs nonclassical = 52.1 vs 31.8 vs 15.3%; Controls - 44 vs 5.8 vs 24%). Non-classical monocytes (CD14dim/CD16+) demonstrated the lowest mean CD11b expression at baseline of any sub-population, in both children with DS and controls. This was significantly lower compared to both intermediate and classical monocyte CD11b in both cohorts.

Effects of LPS endotoxin on TLR4 expression

Neutrophil TLR-4 expression at baseline was not significantly different between children with DS compared to controls (p = 0.57). After LPS incubation there was no significant response in TLR4 expression in either cohort (DS p = 0.15 v Control p = 0.057; Fig. 3a). On comparing the mean percentage rise in TLR-4 expression after LPS, there was a 9.4% rise in children with DS versus 28.7% in the control group (Fig. 5a (p = 0.23)).

Fig. 3

Neutrophil and monocyte Toll-like receptor (TLR-4) expression in response to lipopolysaccharide (LPS) in children with Down syndrome (DS) and controls. Values expressed as mean channel fluorescence (MFI). *p < 0.05. a Neutrophil TLR4 (DS n = 19; Controls n = 10); b Total monocyte TLR-4 (DS n = 22; Controls n = 15); c Classical monocyte TLR4 (DS n = 16; Controls n = 15); d Intermediate monocyte TLR4 (DS n = 15; Controls n = 14); e Non-classical monocyte TLR-4 (DS n = 16; Controls n = 20)

TLR-4 expression on total monocytes did not show any difference at baseline between children with DS and controls (p = 0.24). TLR-4 expression post LPS treatment increased significantly in controls (p = 0.016) but did not reach significance in the children with DS (p = 0.07; Fig. 3b). The mean percentage rise after LPS stimulation was 8.4% in children with DS versus 17.2% in controls ((p = 0.2)) Fig. 5b). Monocyte subset TLR-4 expression analysis revealed no significant differences at baseline or after LPS treatment in classical (CD14+/CD16-) or intermediate (CD14+/CD16+) subpopulations between children with DS and controls (Fig. 3c (p = 0.51), d (p = 0.4) and Fig. 5c (p = 0.75), d (p = 0.84)). Non-classical monocyte (CD14dim/CD16+) TLR-4 expression was found to be significantly higher at baseline in children with DS compared to controls (p = 0.02; Fig. 3e). There were no significant differences in TLR-4 expression after LPS stimulation in either cases or controls (Fig. 5e (p = 0.96)).

The classical monocytes in both cohorts exhibited the largest mean percentage rise in TLR-4 expression after LPS treatment (DS – classical vs intermediate vs non-classical = 15.2 vs 3.6 vs 9.9%; Control - 17.9 vs 1.2 vs 10.7%). Intermediate monocytes had the largest mean TLR-4 MFI at baseline of any monocyte subpopulation in both children with DS and the control group (DS v control: intermediate vs classical p = 0.003 versus 0.005). Non-classical monocytes displayed the lowest mean TLR-4 at baseline of the three monocyte subsets and was significantly lower than intermediate monocyte TLR-4 in both cohorts.

Effects of melatonin on CD11b expression

Neutrophil CD11b expression decreased significantly after melatonin treatment in both cohorts (DS p = < 0.0001; Controls p = < 0.0001), compared with baseline the mean percentage fall in CD11b expression was 25.8% in children with DS versus 23.1% in controls (p = 0.63)). There were no differences in mean percentage fall in CD11b expression when comparing LPS treated samples and those treated with LPS and melatonin in both cohorts (Fig. 4a(p = 0.64)).

Fig. 4

Neutrophil and monocyte CD11b expression in response to LPS and melatonin in children with DS versus controls: Samples were treated with Lipopolysaccharide (LPS), Melatonin (Mel), Lipopolysaccharide and melatonin (LPS + Mel) and Lipopolysaccharide (LPS) versus Lipopolysaccharide and melatonin (LPS/ LPS + Mel) and expressed as fold changes in mean channel fluorescence (MFI). p* < 0.05. a Neutrophil CD11b (DS n = 23; Controls n = 16); b Total monocyte CD11b (DS n = 19; Controls n = 21); c Classical monocyte CD11b (DS n = 19; Controls n = 21); d Intermediate CD11b (DS n = 18; Controls n = 20); e Non-classical monocyte CD11b (DS n = 19; Controls n = 21)

Total monocyte CD11b expression reduced significantly after melatonin incubation in children with DS (n = 12; p = 0.02), but not in the control group (n = 17; p = 0.12). The mean percentage fall in CD11b MFI was 19% in children with DS versus 3.4% in controls (Fig. 4b(p = 0.24)). In classical and intermediate monocytes there were significant decreases in CD11b expression from baseline after melatonin in both cohorts) DS (p = 0.001); Control (p = 0.05); (d) DS (p = 0.02); Control (p = 0.03)]. Non-classical monocytes (CD14dim/CD16-) showed a significant increase in CD11b expression after melatonin in children with DS (p = 0.03), and in controls but not to a significant level in the latter (p = 0.1). The mean percentage rise in CD11b expression after melatonin was 45% in children with DS versus 15.3% in controls (Fig. 4e (p = 0.12)).

Effects of melatonin on TLR-4 expression

Neutrophil TLR-4 expression showed no significant change after melatonin treatment in either group. The mean percentage fall in TLR-4 expression was 4.4% in children with DS and 1.3% in controls (p = 0.82). Comparing LPS and LPS + melatonin treated samples there was a 17.5% mean reduction in TLR-4 expression on neutrophils of children with DS compared to a fall of 4.8% in controls (p = 0.48), Fig. 5a.

Fig. 5

Neutrophil and monocyte TLR-4 expression in response to LPS and melatonin in children with DS versus controls: Samples were treated with Lipopolysaccharide (LPS), Melatonin (Mel), Lipopolysaccharide and melatonin (LPS + Mel) and Lipopolysaccharide (LPS) versus Lipopolysaccharide and melatonin (LPS/ LPS + Mel) and expressed as fold changes in mean channel fluorescence (MFI). a Neutrophil TLR-4 (DS n = 19; Controls n = 10); b Total monocyte TLR-4 (DS n = 22; Controls n = 15); c Classical monocyte TLR-4 (DS n = 16; Controls n = 15); d Intermediate monocyte TLR-4 (DS n = 15; Controls n = 14); e Non-classical monocyte TLR-4 (DS n = 16; Controls n = 20)

Total monocyte TLR-4 was significantly reduced after melatonin incubation in both groups (DS p = 0.03; Controls p = 0.05). The average percentage fall in TLR-4 expression after melatonin treatment was 13% in children with DS versus 11.4% in controls (Fig. 5b (p = 0.81)). Monocyte subset analysis of melatonin on TLR-4 expression showed no significant reduction in either group (Fig. 5c (p = 0.74), d (p = 0.23), e (p = 0.52)).


Neutrophil CD11b expression at baseline was significantly lower in children with DS compared with controls. Following LPS treatment children with DS upregulated CD11b, and this was significantly greater than controls. Novo et al. [18] reported that, at baseline, CD11b expression on neutrophils was not significantly different between children with DS (n = 12) and controls, although the smaller numbers and older population in this study may contribute to these findings. Our research suggests that although the level of CD11b may be lower under normal conditions, after contact with endotoxin there is an increased ability to activate and mobilise neutrophils in response to this stimulus. Neutrophils in children with DS may be hyper-responsive to endotoxin, which may have detrimental effects in the setting of sepsis. Adults with sepsis and renal injury in the absence of hypotension, have been shown to have increased activation of neutrophils with upregulation of CD11b [31], worsening prognosis. Furthermore, neutrophil mediated lung injury in sepsis, and multi-organ dysfunction (MODS) have been associated with increased CD11b expression on these cells [32, 33]. A blockade of this receptor could have potential benefits in these clinical contexts [34]. In paediatric studies LPS hyper-responsiveness has been demonstrated through increased CD11b expression on neutrophils and monocytes of neonates with encephalopathy [35, 36], these infants having developed significant immune dysregulation. Zhou et al. [37] examined TLR4 signalling and the CD11b response on polymorphonuclear cells in mice. The authors concluded that TLR4 mediates CD11b upregulation and is key for PMN activation in response to LPS. Further correlation between CD11b and TLR4 has been described by Guang et al. [38] who reported that CD11b mediates TLR4 signalling and trafficking in a cell specific manner in dendritic cells and macrophages, having a crucial role in balancing the innate and adaptive response to LPS. It appears that the two receptors are inter-linked and have important regulatory roles on one another in initiating the innate immune response.

Zhang et al. [39] demonstrated that mice deficient in CD11b exposed to Mycobacterium tuberculosis developed more severe granulomas, higher leucocyte recruitment and elevated pro-inflammatory cytokines. This demonstrates the immunomodulatory effect neutrophil CD11b expression exerts on the host response to infection. A persistent inflammatory response can be seen in autoimmunity and there is a higher prevalence in DS, recent studies suggest that reduced CD11b is associated with chronic inflammation in SLE and lupus nephritis [40, 41]. Neutrophil CD11b is also decreased in septic shock and correlated with poorer outcomes [42, 43]. In this context, the increased incidence of both autoimmunity and sepsis in DS is particularly noteworthy [16, 44]. We demonstrated that melatonin caused a predominant decrease in CD11b expression in both cohorts; Fig. 4. We also showed that children with DS exhibited a hyper-responsive CD11b response to LPS in neutrophils Fig. 4a. In the acute setting of sepsis/SIRS an upregulation of CD11b may be associated with deleterious effects [45], furthermore, a positive correlation between CD11b expression and the degree of systemic inflammation has been described [46], making melatonin a potential adjunct in acute sepsis/SIRS.

The classical monocyte (CD14+/CD16-) accounts for the largest proportion of monocytes (80–85%) and its main functions include antigen presentation and phagocytosis [47]. We found classical monocytes exhibited significantly higher CD11b expression at baseline, and greater fold increases in CD11b after LPS than other monocyte sub-populations in both groups. This sub-group also displayed the largest rise in TLR-4 after LPS compared with other monocyte subpopulations in both cohorts. This suggests that classical monocytes are significantly pro-inflammatory with the largest CD11b and TLR4 response to LPS than any other sub-population. Regarding differential CD11b expression on monocyte subsets Tak et al. [48] reported no significant differences, whereas another study examining differential in vivo activation of monocyte subsets reported the most significant rise in CD11b on the intermediate monocyte [49]. However, these studies [48, 49] characterised CD11b expression after lower doses of LPS with longer incubations in an adult in vivo setting as compared to our study which was undertaken in a paediatric cohort. Monocyte CD11b was highest on classical and intermediate monocytes [50].

Intermediate monocytes (CD14+/CD16+) are elevated in the setting of acute illness such as sepsis in children [51]. In our study, there was a significant rise in CD11b expression after LPS stimulation in children with DS but not in controls on intermediate monocytes. This adds to the evidence that there are hyper-responsive elements to the innate immune system in children with DS. Indeed, intermediate monocytes produce significant quantities of TNF-α once activated [50]. Previous studies have demonstrated elevated levels of TNF-α in patients with DS compared with healthy controls [13] at baseline. Intermediate monocytes demonstrated the greatest TLR-4 at baseline compared with other monocytes in both groups which has also been demonstrated in adults [20].

Non-classical monocytes (CD14dim/16+) have been implicated in both acute and chronic disease and have a pro-inflammatory phenotype with increased production of IL-1β and TNF-α [47]. This monocyte sub-group had significantly lower CD11b and TLR-4 expression in both groups at baseline. Furthermore, non-classical monocytes demonstrated a relative hypo-responsiveness to LPS versus the other sub-populations. Boyette et al. [50] assessed the phenotype, function, and differentiation monocyte subsets, and reported that non-classical monocytes had the lowest CD11b MFI and that there was the smallest response in this subset following TLR-4 stimulation. We found baseline TLR-4 expression was significantly raised in children with DS versus controls. The TLR-4 response plays a significant role in fighting infection but may also be responsible for the dysregulated inflammation seen in septic shock [52]. Williams et al. noted an increased mortality in mice with polymicrobial sepsis who exhibited early up-regulation of TLR-4, and improved survival in those with suppressed TLR gene expression [53]. Suppression of TLR-4 activation, pro-inflammatory cytokine release, and developing endotoxin tolerance is important in limiting the adverse effects of sepsis. Furthermore, a failure of this protective negative feedback process may contribute to increased mortality in sepsis [54].

We demonstrated that melatonin has an anti-inflammatory influence on innate immune function by reducing CD11b expression on neutrophils and total monocytes in children with DS and controls, thereby inhibiting neutrophil and monocyte activation and migration. Although there is a paucity of literature on the effect of melatonin on CD11b, Alvarez-Sanchez et al. reported a reduction in CD11b in melatonin-treated mice [55]. A significant reduction in TLR-4 expression only occurred in total monocyte populations. Melatonin may act as a TLR-4 antagonist and may be modulated via TLR-4 mediated inflammatory genes through molecule myeloid differentiation factor 88 (MyD88)-dependent and TRIF-dependent signalling pathways [56], thereby attenuating inflammation.

Melatonin has beneficial immunomodulatory effects in the setting of sepsis by inhibiting mitochondrial dysfunction and inflammation, reducing nitrosative and oxidative stress [29]. Melatonin has a robust antioxidant or free radical scavenging activity of [57, 58] and melatonin administration also impairs NF-κB transcriptional activity, reducing pro-inflammatory cytokine (IL-1β, TNF-α, IFN-γ) release and inhibiting activation of the NLRP3 inflammasome [59]. Melatonin improved survival and clinical outcomes in neonates versus controls in sepsis [28, 60, 61]. We have demonstrated that the immunomodulatory effects of melatonin in sepsis can also be broadened to include reducing neutrophil and monocyte activation.

Melatonin increased CD11b expression on non-classical monocytes and to a significant level in the children with DS. However, it has been shown that melatonin can have pro-inflammatory actions in response to endotoxaemia. Effenberger et al. [62] reported that melatonin enhanced the general immune response following LPS treatment. Melatonin may have differing actions on distinct cell lines, with the pro-inflammatory non-classical monocyte being preferentially activated. Further evaluation of the immunomodulatory properties of melatonin in children with DS will allow assessment of its potential as a therapeutic agent.


This research highlights important differences in the innate immunity of children with DS versus age-matched controls. To our knowledge this has not been studied previously in this population. Children with DS have an increased response to LPS in neutrophils and intermediate monocytes, while also having elevated TLR-4 expression on non-classical monocytes compared to controls. These variations may be a contributory factor in a heightened/dysregulated innate immune response, which may have deleterious effects, leading to the worse outcomes seen in sepsis in these children. Lastly, melatonin could represent a useful clinical adjunct in the treatment of sepsis as an immunomodulator and our study suggests its anti-inflammatory effects also influence neutrophil and monocyte function.



Congenital heart disease


Down syndrome




Mean channel fluorescence


Multi organ dysfunction syndrome


Myeloid differentiation factor 88


Not significant


Our lady’s children’s hospital Crumlin


PBS containing 1% bovine serum albumin and 0.02% sodium azide


Phosphate buffered solution


Respiratory tract infections


Standard deviation


Standard error of the mean


Systemic lupus erythematosus


Toll like receptor 4


  1. 1.

    Down’s Syndrome Medical Interest Group (DSMIG) (UK & Ireland), Department of Paediatrics University of Dublin TCTNCsH, Tallaght Hospital. Medical management of children & adolescents with Down syndrome in Ireland 2015.

    Google Scholar 

  2. 2.

    Parker SE, Mai CT, Canfield MA, Rickard R, Wang Y, Meyer RE, et al. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birth defects research part A, clinical and molecular. Teratology. 2010;88(12):1008–16.

    CAS  Google Scholar 

  3. 3.

    van Trotsenburg AS, Heymans HS, Tijssen JG, de Vijlder JJ, Vulsma T. Comorbidity, hospitalization, and medication use and their influence on mental and motor development of young infants with Down syndrome. Pediatrics. 2006;118(4):1633–9.

    Article  Google Scholar 

  4. 4.

    Cruz NV, Mahmoud SA, Chen H, Lowery-Nordberg M, Berlin K, Bahna SL. Follow-up study of immune defects in patients with dysmorphic disorders. Ann Allergy Asthma Immunol. 2009;102(5):426–31.

    Article  Google Scholar 

  5. 5.

    de Hingh YC, van der Vossen PW, Gemen EF, Mulder AB, Hop WC, Brus F, et al. Intrinsic abnormalities of lymphocyte counts in children with Down syndrome. J Pediatr. 2005;147(6):744–7.

    Article  Google Scholar 

  6. 6.

    Murphy M, Epstein LB. Down syndrome (trisomy 21) thymuses have a decreased proportion of cells expressing high levels of TCR alpha, beta and CD3. A possible mechanism for diminished T cell function in Down syndrome. Clin Immunol Immunopathol. 1990;55(3):453–67.

    CAS  Article  Google Scholar 

  7. 7.

    Kusters MA, Bok VL, Bolz WE, Huijskens EG, Peeters MF, de Vries E. Influenza A/H1N1 vaccination response is inadequate in Down syndrome children when the latest cut-off values are used. Pediatr Infect Dis J. 2012;31(12):1284–5.

    Article  Google Scholar 

  8. 8.

    Kusters MA, Jol-Van Der Zijde EC, Gijsbers RH, de Vries E. Decreased response after conjugated meningococcal serogroup C vaccination in children with Down syndrome. Pediatr Infect Dis J. 2011;30(9):818–9.

    Article  Google Scholar 

  9. 9.

    Kusters MA, Jol-van der Zijde CM, van Tol MJ, Bolz WE, Bok LA, Visser M, et al. Impaired avidity maturation after tetanus toxoid booster in children with Down syndrome. Pediatr Infect Dis J. 2011;30(4):357–9.

    Article  Google Scholar 

  10. 10.

    Valentini D, Marcellini V, Bianchi S, Villani A, Facchini M, Donatelli I, et al. Generation of switched memory B cells in response to vaccination in Down syndrome children and their siblings. Vaccine. 2015;33(48):6689–96.

    CAS  Article  Google Scholar 

  11. 11.

    Cetiner S, Demirhan O, Inal TC, Tastemir D, Sertdemir Y. Analysis of peripheral blood T-cell subsets, natural killer cells and serum levels of cytokines in children with Down syndrome. Int J Immunogenet. 2010;37(4):233–7.

    CAS  Article  Google Scholar 

  12. 12.

    Nateghi Rostami M, Douraghi M, Miramin Mohammadi A, Nikmanesh B. Altered serum pro-inflammatory cytokines in children with Down’s syndrome. Eur Cytokine Netw. 2012;23(2):64–7.

    PubMed  Google Scholar 

  13. 13.

    Zhang Y, Che M, Yuan J, Yu Y, Cao C, Qin XY, et al. Aberrations in circulating inflammatory cytokine levels in patients with Down syndrome: a meta-analysis. Oncotarget. 2017;8(48):84489–96.

    Article  Google Scholar 

  14. 14.

    Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol. 2011;164(1):9–16.

    CAS  Article  Google Scholar 

  15. 15.

    Hilton JM, Fitzgerald DA, Cooper DM. Respiratory morbidity of hospitalized children with trisomy 21. J Paediatr Child Health. 1999;35(4):383–6.

    CAS  Article  Google Scholar 

  16. 16.

    Garrison MM, Jeffries H, Christakis DA. Risk of death for children with Down syndrome and sepsis. J Pediatr. 2005;147(6):748–52.

    Article  Google Scholar 

  17. 17.

    Licastro F, Melotti C, Parente R, Davis LJ, Chiricolo M, Zannotti M, et al. Derangement of non-specific immunity in Down syndrome subjects: low leukocyte chemiluminescence activity after phagocytic activation. Am J Med Genet Suppl. 1990;7:242–6.

    CAS  PubMed  Google Scholar 

  18. 18.

    Novo E, Garcia MI, Lavergne J. Nonspecific immunity in Down syndrome: a study of chemotaxis, phagocytosis, oxidative metabolism, and cell surface marker expression of polymorphonuclear cells. Am J Med Genet. 1993;46(4):384–91.

    CAS  Article  Google Scholar 

  19. 19.

    Bloemers BL, van Bleek GM, Kimpen JL, Bont L. Distinct abnormalities in the innate immune system of children with Down syndrome. J Pediatr. 2010;156(5):804–9 9.e1–9.e5.

    CAS  Article  Google Scholar 

  20. 20.

    Mukherjee R, Kanti Barman P, Kumar Thatoi P, Tripathy R, Kumar Das B, Ravindran B. Non-classical monocytes display inflammatory features: validation in sepsis and systemic lupus erythematous. Sci Rep. 2015;5:13886.

    Article  Google Scholar 

  21. 21.

    Carr R. Neutrophil production and function in newborn infants. Br J Haematol. 2000;110(1):18–28.

    CAS  Article  Google Scholar 

  22. 22.

    Romero R, Chaiworapongsa T, Espinoza J. Micronutrients and intrauterine infection, preterm birth and the fetal inflammatory response syndrome. J Nutr. 2003;133(5 Suppl 2):1668s–73s.

    CAS  Article  Google Scholar 

  23. 23.

    O'Hare FM, Watson W, O'Neill A, Grant T, Onwuneme C, Donoghue V, et al. Neutrophil and monocyte toll-like receptor 4, CD11b and reactive oxygen intermediates, and neuroimaging outcomes in preterm infants. Pediatr Res. 2015;78(1):82–90.

    CAS  Article  Google Scholar 

  24. 24.

    Liu Y, Yin H, Zhao M, Lu Q. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin Rev Allergy Immunol. 2014;47(2):136–47.

    CAS  Article  Google Scholar 

  25. 25.

    Escames G, Leon J, Macias M, Khaldy H, Acuna-Castroviejo D. Melatonin counteracts lipopolysaccharide-induced expression and activity of mitochondrial nitric oxide synthase in rats. FASEB J. 2003;17(8):932–4.

    CAS  Article  Google Scholar 

  26. 26.

    Favero G, Franceschetti L, Bonomini F, Rodella LF, Rezzani R. Melatonin as an anti-inflammatory agent modulating Inflammasome activation. Int J Endocrinol. 2017;2017:1835195.

    Article  Google Scholar 

  27. 27.

    Abdelgadir IS, Gordon MA, Akobeng AK. Melatonin for the management of sleep problems in children with neurodevelopmental disorders: a systematic review and meta-analysis. Arch Dis Child. 2018. [Epub ahead of print]

  28. 28.

    El Frargy M, El-Sharkawy HM, Attia GF. Use of melatonin as an adjuvant therapy in neonatal sepsis. J Neonatal-Perinatal Med. 2015;8(3):227–32.

    CAS  Article  Google Scholar 

  29. 29.

    Hu W, Deng C, Ma Z, Wang D, Fan C, Li T, et al. Utilizing melatonin to combat bacterial infections and septic injury. Br J Pharmacol. 2017;174(9):754–68.

    CAS  Article  Google Scholar 

  30. 30.

    Prabhu SB, Rathore DK, Nair D, Chaudhary A, Raza S, Kanodia P, et al. Comparison of human neonatal and adult blood leukocyte subset composition phenotypes. PLoS One. 2016;11(9):e0162242.

    Article  Google Scholar 

  31. 31.

    Rinder CS, Fontes M, Mathew JP, Rinder HM, Smith BR. Neutrophil CD11b upregulation during cardiopulmonary bypass is associated with postoperative renal injury. Ann Thorac Surg. 2003;75(3):899–905.

    Article  Google Scholar 

  32. 32.

    Asaduzzaman M, Zhang S, Lavasani S, Wang Y, Thorlacius H. LFA-1 and MAC-1 mediate pulmonary recruitment of neutrophils and tissue damage in abdominal sepsis. Shock. 2008;30(3):254–9.

    PubMed  Google Scholar 

  33. 33.

    Maekawa K, Futami S, Nishida M, Terada T, Inagawa H, Suzuki S, et al. Effects of trauma and sepsis on soluble L-selectin and cell surface expression of L-selectin and CD11b. J Trauma. 1998;44(3):460–8.

    CAS  Article  Google Scholar 

  34. 34.

    Maiguel D, Faridi MH, Wei C, Kuwano Y, Balla KM, Hernandez D, et al. Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease. Sci Signal. 2011;4(189):ra57.

    Article  Google Scholar 

  35. 35.

    O'Hare FM, Watson RW, O'Neill A, Blanco A, Donoghue V, Molloy EJ. Persistent systemic monocyte and neutrophil activation in neonatal encephalopathy. J Matern Fetal Neonatal Med. 2016;29(4):582–9.

    CAS  Article  Google Scholar 

  36. 36.

    Eliwan HO, Watson RWG, Aslam S, Regan I, Philbin B, O'Hare FM, et al. Neonatal brain injury and systemic inflammation: modulation by activated protein C ex vivo. Clin Exp Immunol. 2015;179(3):477–84.

    CAS  Article  Google Scholar 

  37. 37.

    Zhou X, Gao XP, Fan J, Liu Q, Anwar KN, Frey RS, et al. LPS activation of toll-like receptor 4 signals CD11b/CD18 expression in neutrophils. Am J Phys Lung Cell Mol Phys. 2005;288(4):L655–62.

    CAS  Google Scholar 

  38. 38.

    Ling GS, Bennett J, Woollard KJ, Szajna M, Fossati-Jimack L, Taylor PR, et al. Integrin CD11b positively regulates TLR4-induced signalling pathways in dendritic cells but not in macrophages. Nat Commun. 2014;5:3039.

    Article  Google Scholar 

  39. 39.

    Zhang Q, Lee W-B, Kang J-S, Kim LK, Kim Y-J. Integrin CD11b negatively regulates Mincle-induced signaling via the Lyn–SIRPα–SHP1 complex. Exp Mol Med. 2018;50(2):e439.

    CAS  Article  Google Scholar 

  40. 40.

    Faridi MH, Khan SQ, Zhao W, Lee HW, Altintas MM, Zhang K, et al. CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus. J Clin Invest. 2017;127(4):1271–83.

    Article  Google Scholar 

  41. 41.

    Khan SQ, Khan I, Gupta V. CD11b activity modulates pathogenesis of lupus nephritis. Front Med. 2018;5:52.

    Article  Google Scholar 

  42. 42.

    Muller Kobold AC, Tulleken JE, Zijlstra JG, Sluiter W, Hermans J, Kallenberg CG, et al. Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med. 2000;26(7):883–92.

    CAS  Article  Google Scholar 

  43. 43.

    Chishti AD, Shenton BK, Kirby JA, Baudouin SV. Neutrophil chemotaxis and receptor expression in clinical septic shock. Intensive Care Med. 2004;30(4):605–11.

    Article  Google Scholar 

  44. 44.

    Pellegrini FP, Marinoni M, Frangione V, Tedeschi A, Gandini V, Ciglia F, et al. Down syndrome, autoimmunity and T regulatory cells. Clin Exp Immunol. 2012;169(3):238–43.

    CAS  Article  Google Scholar 

  45. 45.

    Rosenbloom AJ, Pinsky MR, Napolitano C, Nguyen TS, Levann D, Pencosky N, et al. Suppression of cytokine-mediated beta2-integrin activation on circulating neutrophils in critically ill patients. J Leukoc Biol. 1999;66(1):83–9.

    CAS  Article  Google Scholar 

  46. 46.

    Delanghe JR, Speeckaert MM. Translational research and biomarkers in neonatal sepsis. Clin Chim Acta. 2015;451(Pt A):46–64.

    CAS  Article  Google Scholar 

  47. 47.

    Wong KL, Yeap WH, Tai JJ, Ong SM, Dang TM, Wong SC. The three human monocyte subsets: implications for health and disease. Immunol Res. 2012;53(1–3):41–57.

    CAS  Article  Google Scholar 

  48. 48.

    Tak T, van Groenendael R, Pickkers P, Koenderman L. Monocyte subsets are differentially lost from the circulation during acute inflammation induced by human experimental endotoxemia. J Innate Immun. 2017;9(5):464–74.

    CAS  Article  Google Scholar 

  49. 49.

    Thaler B, Hohensinner PJ, Krychtiuk KA, Matzneller P, Koller L, Brekalo M, et al. Differential in vivo activation of monocyte subsets during low-grade inflammation through experimental endotoxemia in humans. Sci Rep. 2016;6:30162.

    CAS  Article  Google Scholar 

  50. 50.

    Boyette LB, Macedo C, Hadi K, Elinoff BD, Walters JT, Ramaswami B, et al. Phenotype, function, and differentiation potential of human monocyte subsets. PLoS One. 2017;12(4):e0176460.

    Article  Google Scholar 

  51. 51.

    Skrzeczynska J, Kobylarz K, Hartwich Z, Zembala M, Pryjma J. CD14+CD16+ monocytes in the course of sepsis in neonates and small children: monitoring and functional studies. Scand J Immunol. 2002;55(6):629–38.

    CAS  Article  Google Scholar 

  52. 52.

    Rosadini CV, Kagan JC. Early innate immune responses to bacterial LPS. Curr Opin Immunol. 2017;44:14–9.

    CAS  Article  Google Scholar 

  53. 53.

    Williams DL, Ha T, Li C, Kalbfleisch JH, Schweitzer J, Vogt W, et al. Modulation of tissue toll-like receptor 2 and 4 during the early phases of polymicrobial sepsis correlates with mortality. Crit Care Med. 2003;31(6):1808–18.

    Article  Google Scholar 

  54. 54.

    Skinner NA, MacIsaac CM, Hamilton JA, Visvanathan K. Regulation of toll-like receptor (TLR)2 and TLR4 on CD14dimCD16+ monocytes in response to sepsis-related antigens. Clin Exp Immunol. 2005;141(2):270–8.

    CAS  Article  Google Scholar 

  55. 55.

    Alvarez-Sanchez N, Cruz-Chamorro I, Lopez-Gonzalez A, Utrilla JC, Fernandez-Santos JM, Martinez-Lopez A, et al. Melatonin controls experimental autoimmune encephalomyelitis by altering the T effector/regulatory balance. Brain Behav Immun. 2015;50:101–14.

    CAS  Article  Google Scholar 

  56. 56.

    Xia MZ, Liang YL, Wang H, Chen X, Huang YY, Zhang ZH, et al. Melatonin modulates TLR4-mediated inflammatory genes through MyD88- and TRIF-dependent signaling pathways in lipopolysaccharide-stimulated RAW264.7 cells. J Pineal Res. 2012;53(4):325–34.

    CAS  Article  Google Scholar 

  57. 57.

    Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. 2016;61(3):253–78.

    CAS  Article  Google Scholar 

  58. 58.

    Manchester LC, Coto-Montes A, Boga JA, Andersen LP, Zhou Z, Galano A, et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res. 2015;59(4):403–19.

    CAS  Article  Google Scholar 

  59. 59.

    Volt H, Garcia JA, Doerrier C, Diaz-Casado ME, Guerra-Librero A, Lopez LC, et al. Same molecule but different expression: aging and sepsis trigger NLRP3 inflammasome activation, a target of melatonin. J Pineal Res. 2016;60(2):193–205.

    CAS  Article  Google Scholar 

  60. 60.

    Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi P, et al. Effects of melatonin treatment in septic newborns. Pediatr Res. 2001;50(6):756–60.

    CAS  Article  Google Scholar 

  61. 61.

    El-Gendy FM, El-Hawy MA, Hassan MG. Beneficial effect of melatonin in the treatment of neonatal sepsis. J Matern Fetal Neonatal Med. 2018;31(17):2299–303.

    CAS  Article  Google Scholar 

  62. 62.

    Effenberger-Neidnicht K, Brencher L, Broecker-Preuss M, Hamburger T, Petrat F, de Groot H. Immune stimulation by exogenous melatonin during experimental endotoxemia. Inflammation. 2014;37(3):738–44.

    CAS  PubMed  Google Scholar 

Download references




This study was funded by the National Children’s Research Centre (NCRC), Crumlin, Dublin 12 and the National Children’s Hospital Fund, Tallaght, Dublin, Ireland.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Author information




The manuscript is being submitted on behalf of all the authors and is the original work of all authors. DH was responsible for recruitment, sample acquistion, lab experiments, analysis and was responsible for writing the main draft of the manuscript. FM, NL, ER, JB, OF were responsible for patient recruitment, sample acquisition, reviewing and editing the manuscript. AM, and AMM provided expertise in sample analysis on the flow cytometer, review of those results and of the manuscript. TRL, DD and EM were instrumental in study design, supervising the research and its outcomes and providing key editorial assistance. All authors had editorial license to review and re-draft the manuscript, and all contributors had to approve the final edit. All authors are accountable for the accuracy and scientific integrity of this work.

Corresponding author

Correspondence to Dean Huggard.

Ethics declarations

Ethics approval and consent to participate

Our research involved whole blood samples from paediatric patients. Ethical approval was received in advance by the research and ethics committees from Our lady’s children’s hospital Crumlin (Ref: GEN 565/17), and the SJH.AMNCH ethics committee (Ref: 2017–05). Approval Letters available on request.

All participant’s parents received an information leaflet and full written consent was obtained prior to enrolment in the study.

Consent for publication


Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Huggard, D., McGrane, F., Lagan, N. et al. Altered endotoxin responsiveness in healthy children with Down syndrome. BMC Immunol 19, 31 (2018).

Download citation


  • Down syndrome
  • Inflammation
  • Endotoxin
  • Innate immunity
  • Immunomodulation